Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00059293
Other study ID # 1208
Secondary ID R01HL072946
Status Completed
Phase
First received
Last updated
Start date September 2002
Est. completion date July 2008

Study information

Verified date July 2008
Source National Heart, Lung, and Blood Institute (NHLBI)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To use transcranial Doppler (TCD) ultrasound to detect stroke risk in children with sickle cell disease.


Description:

BACKGROUND:

Cerebral vasculopathy and stroke are among the most serious complications of sickle cell disease. Not every patient will develop central nervous system disease but most children have some evidence of cognitive impairment and about 10% will have overt stroke if this is not forestalled by transcranial Doppler (TCD) screening, identification of individuals at greatest risk by estimating maximal cerebral blood flow and commencing prophylactic transfusion. The basis of these recommendations is studies in children over age 2-years where stroke is most prevalent. Transfusion is not without its own serious and considerable risks so that other measures for delaying or preventing cerebral vasculopathy would be valuable. Hydroxyurea (HU) can reduce both morbidity and mortality of sickle cell anemia in adults; most likely the same pertains in children. Unknown are the effects of HU in infants and the youngest children and whether its successful use can reduce the risks of sickle cerebrovascular disease. If HU is associated with reduced TCD velocity, and if it is safe in infants, the medical implications would be high.

Baby TCD is an ancillary study to the initial phase of BABY HUG, a multicenter clinical trial funded by the NHLBI. In BABY HUG, infants (12-17 months old) with sickle cell disease (SCD) will be randomized to either hydroxyurea (HU) or placebo and followed for 24 months. There is broad interest in the effect of hydroxyurea on the central nervous system in the children being studied. Stroke occurs after age 1 year and there is evidence that the process of cerebrovascular disease starts very early in some patients. The Cooperative Study of Sickle Cell Disease documented a high risk of incident stroke in the 2-6 year age group. The study is in response to an initiative on Ancillary Studies in Heart, Lung, and Blood Disease Trials released in June, 2000.

DESIGN NARRATIVE:

The study will perform TCD on the 40 children in BABY HUG at baseline and at the end of study. TCD has proven very useful in estimation of stroke risk in children with SCD ages 2-16 years, and is at the center of a paradigm of primary stroke prevention recommended by the National Heart, Lung, and Blood Institute based on the STOP study. If stroke risk could be detected at an earlier stage (i.e., younger than the 2-16 year-old subjects in STOP), then physicians would be able to provide preventive treatment at an earlier stage of the disease. TCD will be performed before and after 24 months of treatment. TCD performance and reading will be centrally controlled and STOP-consistent. The investigators have experience in TCD of infants, the age targeted by the parent study. TCD will be compared between HU and control groups, before and after treatment. In addition, the investigators have access to data from over 400 children in the 2-4 year age range from the STOP screening program performed in the mid- to late 1990s. Since these patients were not on HU or transfusion this dataset will be used to give an estimate of the prevalence of high stroke risk without HU treatment, and can be compared to the HU group in Baby HUG, adding another important comparative dimension to the analyses. Although the sample size is purposely small as designed by the parent study, large differences in the prevalence of high-risk patients at the end of treatment could be detected by Baby TCD.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date July 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender All
Age group 1 Year to 2 Years
Eligibility No eligibility criteria

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
See also
  Status Clinical Trial Phase
Completed NCT03239847 - Cost Effectiveness of the EndoPhys Pressure Sensing Access System vs. Radial A-line for Intra-operative Blood Pressure Monitoring N/A
Recruiting NCT03544801 - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting NCT06010823 - Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Recruiting NCT02472028 - Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals Phase 4
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Active, not recruiting NCT01555411 - Akershus Cardiac Examination (ACE) 1950 Study
Completed NCT01304576 - Orientation Agnosia: Clinical and Anatomical Study N/A
Completed NCT00049894 - Predictors of Recurrent Stroke in the PROGRESS Study N/A
Completed NCT00049920 - The ARIC MRI Study N/A
Completed NCT00005562 - Coronary Artery Calcium, Exercise Tests, and CHD Outcome N/A
Completed NCT00005395 - Honolulu Heart Program-Study of Stroke and Dementia N/A
Completed NCT00000479 - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Phase 3
Completed NCT00005140 - Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago N/A
Enrolling by invitation NCT00005485 - The Jackson Heart Study of Cardiovascular Disease Among African Americans
Recruiting NCT06275113 - BRING-UP Prevention
Completed NCT02702635 - Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging N/A
Recruiting NCT04336852 - Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function N/A
Not yet recruiting NCT05892510 - Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke Phase 2/Phase 3
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A